MBio to Seek FDA Approval for LightDeck® Platform

Future Use in Outbreak Management Expected, via DARPA Partnership

Boulder, CO, April 6, 2020 – MBio Diagnostics today announced an expanded scope contract with the US Defense Advanced Research Projects Agency (DARPA), where DARPA will apply additional resources and funds to accelerate progress towards FDA approval for MBio’s LightDeck® platform. Read more in MBio Diagnostic press release.

Categories: Ecosystem News